Article in Nature immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
Stephanie Grebinoski *Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Angela M Gocher-Demske *Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Dario A A Vignali *Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. dvignali@pitt.edu.ORCID http://orcid.org/0000-0002-2771-5992
University of Pittsburgh · US
Funding
Synergies among inhibitory receptors in tolerance, cancer & antiviral immunityP01AI108545 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI E. John Wherry · 2015 to 2026
$30.8M
Training in Cellular & Molecular Mechanisms of Tumor RejectionT32CA082084 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Robert J Binder, Dario AA Vignali · 1999 to 2026
$9.2M
Autoimmunity and Immunopathology Training ProgramT32AI089443 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHLOMCHIK, MARK J · 2010 to 2024
$6.6M
Structure, Function and Mechanistic Analysis of LAG3R01AI144422 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Roy A Mariuzza, Dario AA Vignali · 2019 to 2026
$5.9M
Regulatory T cells and the tumor microenvironmentR35CA263850 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Dario AA Vignali · 2021 to 2026
$5.4M
Structure and Activation of a Multiprotein Signaling ComplexR01AI129893 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI MARIUZZA, ROY A, ORBAN, JOHN · 2017 to 2021
$3.5M
Parameters that Underlie Treg Insufficiency in Autoimmune DiabetesR01DK089125 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VIGNALI, DARIO AA · 2011 to 2020
$2.9M
Production of Interferon Gamma by Regulatory T Cells Mediates Response to ImmunotherapyF32CA247004 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GOCHER-DEMSKE, ANGELA MARIE · 2020 to 2022
$206k
Investigating a disintegrin and metalloproteinase-mediated Neuropilin 1 cleavage in autoimmune diabetesF31AI147638 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GREBINOSKI, STEPHANIE · 2019 to 2021
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Catch and release: freeing up PD-L1 ameliorates autoimmunity. · full record | OpenQuestion